GLP-1 Weight-Loss Drugs Pose New Real-World Risks

Recent studies show that GLP-1 weight-loss drugs such as semaglutide and tirzepatide are less effective in real-world use, with most patients losing only 5-7% of their body weight compared to over 20% in clinical trials. Bariatric surgery remains more effective and durable, averaging a 24-26.5% reduction after two to three years. High discontinuation rates for GLP-1 drugs are influenced by cost, side effects, and lack of consistent follow-up. Increased use of these medications has led to a rise in body lift surgeries to address excess skin. There are also growing concerns about rare but serious vision complications and worsening eating disorders linked to GLP-1 drugs. Experts recommend holistic, multidisciplinary approaches and call for more real-world data to inform treatment decisions.